Highlights Kintor Pharmaceutical Limited

Equities

9939

KYG5273B1077

Market Closed - Hong Kong S.E. Other stock markets 04:08:08 2024-06-04 am EDT			5-day change	1st Jan Change
1.2 ^HKD	-0.83%		-1.64%	-26.38%

12:54pm	Kintor Pharma Receives Standard Cosmetic Ingredient Name for KX-826 Product	MT
May. 24	Kintor Pharmaceutical's Androgenic Alopecia Drug Gets Regulatory Nod; Share Prices Shoot 10%	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kintor Pharmaceutical Limited Announces That the Clinical Trial of Its In-House Developed and Potential First-In-Class Kx-826 Tincture 1.0% for the Treatment of Male Adult Androgenetic Alopecia ("Aga") in China (The "Clinical Trial") Was Cleared by the National Medical Products Administration (The "Nmpa") Recently	May. 24	CI
Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint	Apr. 21	CI
Kintor Pharmaceutical Concludes Phase II Clinical Trial for Androgenic Alopecia Treatment	Apr. 21	MT
Kintor Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Kintor Pharmaceutical Limited Announces Phase Ib/III Clinical Trial of KX-826 and Minoxidil Combination Therapy for the Treatment of Men Adults Receives Clearance by China NMPA	Feb. 01	CI
Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia	Nov. 26	CI
Kintor Pharmaceutical Limited Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China	23-10-11	CI
Kintor Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Kintor Pharma Announces Completion of Patient Enrollment in Phase Ii Clinical Trial of Gt20029 for Treatment of Androgenetic Alopecia in China	23-08-22	CI
Kintor Pharmaceutical Limited Announces Completion of First Patient Enrollment in Long-Term Safety Trial of Kx-826	23-07-19	CI
Kintor Pharmaceutical Limited Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US	23-05-11	CI
Kintor Pharmaceutical Limited Announces Successful Completion of Phase I Clinical Trial of GT1708F for Treatment of Hematological Malignancies in China	23-05-08	CI
Kintor Pharmaceutical Limited Announces Completion of First Subject Enrollment in Phase II Clinical Trial of AR-PROTAC (GT20029 ) for Treatment of Men Androgenetic Alopecia in China	23-04-14	CI
Kintor Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China	23-03-28	CI
Kintor Pharma's KX-826 and GT20029 for Treatment of Androgenetic Alopecia and Acne Presented at AAD 2023	23-03-21	CI
Kintor Pharmaceutical Limited Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World's First Topical Use PROTAC Compound	23-02-10	CI
Kintor Pharmaceutical Limited Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met	22-12-01	CI
Kintor Pharmaceutical Limited Announces Top-Line Results of Phase I Clinical Trial of Gt20029 in China	22-11-23	CI
Kintor Pharmaceutical Limited Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of Gt20029 in the U.S	22-10-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kintor Pharmaceutical Limited

Equities

9939

KYG5273B1077

Highlights

Filters